The mainstay therapy for Borsa da Lavoro locally advanced non-small cell lung cancer is concurrent chemoradiotherapy.Loco-regional recurrence constitutes the predominant failure patterns.Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival.
However, the Humidity Pack large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.